Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

84.91
-3.6800-4.15%
Post-market: 85.240.3300+0.39%19:54 EDT
Volume:1.28M
Turnover:109.22M
Market Cap:11.96B
PE:-37.18
High:88.25
Open:87.99
Low:84.20
Close:88.59
52wk High:95.49
52wk Low:21.61
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.31
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:25.69
PE(LYR):-6,963.83

Loading ...

U.S. Research Roundup-alphabet, IBM, Tesla

Reuters
·
Jul 23

Arrowhead Pharmaceuticals : Piper Sandler Raises Target Price to $126 from $110

THOMSON REUTERS
·
Jul 23

NASDAQ Net Change Percentage Gainers & Losers

Dow Jones
·
Jul 23

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Arrowhead Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 23

Top Midday Gainers

MT Newswires Live
·
Jul 23

Arrowhead Pharma Shares Rise After Positive Results for Triglyceride Drug Plozasiran Trials

Dow Jones
·
Jul 23

Arrowhead price target raised to $115 from $90 at Chardan

TIPRANKS
·
Jul 23

Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results

TIPRANKS
·
Jul 23

Arrowhead rises 23.4%

TIPRANKS
·
Jul 23

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co (OTSKY)

TIPRANKS
·
Jul 22

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 19.25% in Regular Trading, Core Pipeline Plozasiran Achieves Key Late-Stage Trial Endpoints

Market Focus
·
Jul 22

Arrowhead Pharmaceuticals Shares up 18.1% Premarket After Blood-fat Drug Meets Late-stage Trial Goals

THOMSON REUTERS
·
Jul 22

Arrowhead Rises After Blood-fat Drug Meets Late-stage Trial Goals

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 8.64% in Pre-Market Trading, Core Pipeline Plozasiran Delivers Strong Results Across Multiple Key Trials

Market Focus
·
Jul 22

Arrowhead Pharma Announces Press Release on Plozasiran Phase 3 Shasta-3 and Shasta-4 Topline Results

Reuters
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Shows Significant Reduction in Acute Pancreatitis Events, 100% in High-risk Patients

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Demonstrates Consistent Safety Profile with no New Safety Signals

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Achieves 79% and 81% Median Triglyceride Reduction in Shasta-3 and Shasta-4

THOMSON REUTERS
·
Jul 22